Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
ABC-AF Bleeding ScoreABC-AF Stroke ScoreABCD2 ScoreADD-RSAortic Valve Calcium ScoreAPPLE ScoreASCVD (Pooled Cohort)AVA (Continuity Equation)BAG-AHF ScoreBiplane Simpson EFBlood Pressure PercentilesBrugada Criteria (VT vs SVT)Cardiac Output IndexCHA2DS2-VAScCHADS2Cornell Voltage CriteriaCRUSADE Bleeding ScoreDAPT ScoreDASIDuke Treadmill ScoreE/A RatioEDACS ScoreEHMRGEHRA ScoreEmbolic Risk ScoreEROA (PISA Method)FFR (Fractional Flow Reserve)Fick Cardiac OutputFramingham 10-Year RiskFriedewald LDL EquationGorlin EquationGRACE ScoreGupta MICA (NSQIP)GWTG-HF ScoreH2FPEF ScoreHakki FormulaHAS-BLEDHEART PathwayHEART ScoreHEMORR2HAGEShs-Troponin 0h/1h ESC AlgorithmiFRINTERCHEST ScoreKillip ClassificationLee's RCRILV Mass IndexLV Stroke Work IndexMAGGIC Risk ScoreMAP CalculatorMartin/Hopkins LDLModified Duke CriteriaModified Sgarbossa CriteriaMVA (Pressure Half-Time)Non-HDL CholesterolNT-proBNP Age-Adjusted ThresholdsORBIT ScoreOttawa Heart Failure RiskPREVENT EquationsPulse PressurePVR CalculatorPVR IndexQRISK3QTc (Bazett)QTc (Fridericia)REVEAL 2.0 ScoreREVEAL Lite 2Reynolds Risk ScoreROSIRVSP CalculatorSchwartz Score (LQTS)SCORE2Seattle Heart Failure Model (SHFM)Sgarbossa CriteriaShock IndexSokolow-Lyon VoltageStroke Volume IndexSVR CalculatorSYNTAX ScoreSYNTAX Score IITAPSETeichholz FormulaTIMI (STEMI)TIMI (UA/NSTEMI)Troponin Delta CalculatorValvular GradientsVancouver Chest Pain RuleVereckei AlgorithmWATCHDM ScoreWilkins ScoreWood Units Calculator
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

Martin/Hopkins LDL

Martin/Hopkins LDL: Improved LDL estimation with adjusted TG:VLDL ratio, especially accurate at low triglycerides.

Formula

VLDL = TG / adjusted_divisor
LDL = TC − HDL − VLDL

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

When to Use

LDL calculation when triglycerides <400 mg/dL
Particularly useful when TG <150 mg/dL (superior to Friedewald)
Fine-tuning of dyslipidaemia assessment
Research-grade lipid analysis; evolving clinical adoption

Advantages Over Friedewald

Adjustable TG:VLDL ratio based on TG levels (not fixed 5:1)
More accurate at low triglycerides (<150 mg/dL)
Better prediction of cardiovascular risk in lean phenotypes
Particularly useful in HFpEF and diabetes populations

How it Works

Formula

VLDL = TG / adjusted divisor Adjusted divisor varies by TG range: TG <100: divisor ≈ 5.6 TG 100–150: divisor ≈ 5.3 TG 150–200: divisor ≈ 5.0 TG 200–400: divisor ≈ 4.6 LDL = TC − HDL − VLDL

Comparison to Friedewald

Triglyceride LevelFriedewald DivisorHopkins Divisor
<100 mg/dL5.0 (fixed)5.6 (adjusted)
150–200 mg/dL5.0 (fixed)5.0
>200 mg/dL5.0 (fixed)<5.0 (adjusted)

Clinical Pearls

When to Prefer Martin/Hopkins

Patients with low triglycerides on statin/ezetimibe therapy
Lean or athletic individuals (naturally low TG)
Women (typically lower TG than men)
Patients on PCSK9 inhibitors or bempedoic acid (aggressive LDL lowering)

Limitations

Not widely adopted in routine clinical labs (yet)
Requires TG <400 for accuracy; unreliable if TG >400
Limited long-term outcome validation vs. Friedewald
More relevant for research than acute clinical decisions

Next Steps

Therapy Adjustments

If Martin/Hopkins LDL significantly lower than Friedewald → may have greater residual risk than calculated
Use for better risk stratification in guidelines (ACC/AHA target LDL <70 post-ACS)
Particularly valuable when assessing statin/ezetimibe/PCSK9i response
Consider sequential assessment over single calculation

Complementary Calculators

Friedewald LDL Equation
Non-HDL Cholesterol
ASCVD Risk — Pooled Cohort Equations (PCE)
SCORE2 CVD Risk

The Evidence

Primary Publication

Comparison of a Novel Method vs. the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile.

Martin SS et al. • JAMA.. 2013;n=1.35 million. Validated the superior accuracy of the adjustable divisor approach.

Origins & History

Development

Developed by Dr. Steven Martin at Johns Hopkins, published in 2013. Represents a refinement of the decades-old Friedewald equation to accommodate modern dyslipidaemia phenotypes and aggressive lipid lowering strategies.

Last Comprehensive Review: 2026-07-17

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

When to Use

LDL calculation when triglycerides <400 mg/dL
Particularly useful when TG <150 mg/dL (superior to Friedewald)
Fine-tuning of dyslipidaemia assessment
Research-grade lipid analysis; evolving clinical adoption

Advantages Over Friedewald

Adjustable TG:VLDL ratio based on TG levels (not fixed 5:1)
More accurate at low triglycerides (<150 mg/dL)
Better prediction of cardiovascular risk in lean phenotypes
Particularly useful in HFpEF and diabetes populations

How it Works

Formula

VLDL = TG / adjusted divisor Adjusted divisor varies by TG range: TG <100: divisor ≈ 5.6 TG 100–150: divisor ≈ 5.3 TG 150–200: divisor ≈ 5.0 TG 200–400: divisor ≈ 4.6 LDL = TC − HDL − VLDL

Comparison to Friedewald

Triglyceride LevelFriedewald DivisorHopkins Divisor
<100 mg/dL5.0 (fixed)5.6 (adjusted)
150–200 mg/dL5.0 (fixed)5.0
>200 mg/dL5.0 (fixed)<5.0 (adjusted)

Clinical Pearls

When to Prefer Martin/Hopkins

Patients with low triglycerides on statin/ezetimibe therapy
Lean or athletic individuals (naturally low TG)
Women (typically lower TG than men)
Patients on PCSK9 inhibitors or bempedoic acid (aggressive LDL lowering)

Limitations

Not widely adopted in routine clinical labs (yet)
Requires TG <400 for accuracy; unreliable if TG >400
Limited long-term outcome validation vs. Friedewald
More relevant for research than acute clinical decisions

Next Steps

Therapy Adjustments

If Martin/Hopkins LDL significantly lower than Friedewald → may have greater residual risk than calculated
Use for better risk stratification in guidelines (ACC/AHA target LDL <70 post-ACS)
Particularly valuable when assessing statin/ezetimibe/PCSK9i response
Consider sequential assessment over single calculation

Complementary Calculators

Friedewald LDL Equation
Non-HDL Cholesterol
ASCVD Risk — Pooled Cohort Equations (PCE)
SCORE2 CVD Risk

The Evidence

Primary Publication

Comparison of a Novel Method vs. the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile.

Martin SS et al. • JAMA.. 2013;n=1.35 million. Validated the superior accuracy of the adjustable divisor approach.

Origins & History

Development

Developed by Dr. Steven Martin at Johns Hopkins, published in 2013. Represents a refinement of the decades-old Friedewald equation to accommodate modern dyslipidaemia phenotypes and aggressive lipid lowering strategies.

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

JAMAJul 21, 2026
Correction to Primary Composite Outcome in a Trial of Transfusion Strategy

Clinical Context

We think this might be relevant to the clinical guidance for Martin/Hopkins LDL Calculation.

JAMAJul 21, 2026
PCOS Is Now Called PMOS

Clinical Context

We think this has broad domain relevance to Martin/Hopkins LDL Calculation.

WHO NewsJul 21, 2026
UN report: Global hunger levels ease for third consecutive year as regional disparities persist

Clinical Context

We think this has broad domain relevance to Martin/Hopkins LDL Calculation.